Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
3.330
-0.080 (-2.35%)
At close: May 12, 2025, 4:00 PM
3.330
0.00 (0.00%)
After-hours: May 12, 2025, 4:00 PM EDT
Nanobiotix Employees
Nanobiotix had 108 employees as of December 31, 2024. The number of employees increased by 6 or 5.88% compared to the previous year.
Employees
108
Change (1Y)
6
Growth (1Y)
5.88%
Revenue / Employee
n/a
Profits / Employee
-$653,123
Market Cap
163.94M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NBTX News
- 19 hours ago - Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 7 days ago - Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer - GlobeNewsWire
- 12 days ago - Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call - GlobeNewsWire
- 5 weeks ago - Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewsWire
- 6 weeks ago - NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - GlobeNewsWire
- 6 weeks ago - Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC - GlobeNewsWire
- 7 weeks ago - NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference - GlobeNewsWire